vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and H2O AMERICA (HTO). Click either name above to swap in a different company.
H2O AMERICA is the larger business by last-quarter revenue ($199.4M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 8.1%, a 5.2% gap on every dollar of revenue. On growth, H2O AMERICA posted the faster year-over-year revenue change (1.5% vs -1.8%). Over the past eight quarters, H2O AMERICA's revenue compounded faster (15.3% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
H2O Wireless is a United States-based prepaid cell phone service, that utilizes the AT&T network. It is a brand of the mobile virtual network operator (MVNO) Locus Telecommunications, a subsidiary of Telrite Holdings, Inc., since 2019. Locus was formerly a subsidiary of KDDI America corporation, starting in 2010. H2O Wireless is primarily advertised as a non-restrictive phone service for customers to bring or buy unlocked smartphones, although AT&T contract/locked phones may be accepted as well.
AMPH vs HTO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $199.4M |
| Net Profit | $24.4M | $16.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 16.6% |
| Net Margin | 13.3% | 8.1% |
| Revenue YoY | -1.8% | 1.5% |
| Net Profit YoY | -35.7% | -29.2% |
| EPS (diluted) | $0.51 | $0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $199.4M | ||
| Q3 25 | $191.8M | $243.5M | ||
| Q2 25 | $174.4M | $197.8M | ||
| Q1 25 | $170.5M | $164.9M | ||
| Q4 24 | $186.5M | $196.5M | ||
| Q3 24 | $191.2M | $216.7M | ||
| Q2 24 | $182.4M | $173.1M | ||
| Q1 24 | $171.8M | $150.0M |
| Q4 25 | $24.4M | $16.2M | ||
| Q3 25 | $17.4M | $45.1M | ||
| Q2 25 | $31.0M | $24.7M | ||
| Q1 25 | $25.3M | $16.6M | ||
| Q4 24 | $38.0M | $22.9M | ||
| Q3 24 | $40.4M | $38.7M | ||
| Q2 24 | $37.9M | $20.7M | ||
| Q1 24 | $43.2M | $11.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 16.6% | ||
| Q3 25 | 13.2% | 26.5% | ||
| Q2 25 | 24.2% | 22.2% | ||
| Q1 25 | 21.9% | 21.8% | ||
| Q4 24 | 24.2% | 22.2% | ||
| Q3 24 | 29.8% | 26.9% | ||
| Q2 24 | 30.3% | 23.4% | ||
| Q1 24 | 27.9% | 18.6% |
| Q4 25 | 13.3% | 8.1% | ||
| Q3 25 | 9.0% | 18.5% | ||
| Q2 25 | 17.8% | 12.5% | ||
| Q1 25 | 14.8% | 10.0% | ||
| Q4 24 | 20.4% | 11.7% | ||
| Q3 24 | 21.1% | 17.8% | ||
| Q2 24 | 20.8% | 12.0% | ||
| Q1 24 | 25.1% | 7.8% |
| Q4 25 | $0.51 | $0.45 | ||
| Q3 25 | $0.37 | $1.27 | ||
| Q2 25 | $0.64 | $0.71 | ||
| Q1 25 | $0.51 | $0.49 | ||
| Q4 24 | $0.74 | $0.70 | ||
| Q3 24 | $0.78 | $1.17 | ||
| Q2 24 | $0.73 | $0.64 | ||
| Q1 24 | $0.81 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $20.7M |
| Total DebtLower is stronger | $608.7M | $1.9B |
| Stockholders' EquityBook value | $788.8M | $1.5B |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.77× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $20.7M | ||
| Q3 25 | $276.2M | $11.3M | ||
| Q2 25 | $231.8M | $19.8M | ||
| Q1 25 | $236.9M | $23.7M | ||
| Q4 24 | $221.6M | $11.1M | ||
| Q3 24 | $250.5M | $4.0M | ||
| Q2 24 | $217.8M | $22.8M | ||
| Q1 24 | $289.6M | $4.5M |
| Q4 25 | $608.7M | $1.9B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.7B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.5B | ||
| Q3 25 | $776.7M | $1.5B | ||
| Q2 25 | $757.5M | $1.5B | ||
| Q1 25 | $751.3M | $1.4B | ||
| Q4 24 | $732.3M | $1.4B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.7B | $5.0B | ||
| Q2 25 | $1.6B | $4.8B | ||
| Q1 25 | $1.6B | $4.7B | ||
| Q4 24 | $1.6B | $4.7B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.5B | $4.4B | ||
| Q1 24 | $1.6B | $4.4B |
| Q4 25 | 0.77× | 1.23× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.26× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $63.5M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 3.92× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $63.5M | ||
| Q3 25 | $52.6M | $77.3M | ||
| Q2 25 | $35.6M | $60.8M | ||
| Q1 25 | $35.1M | $43.2M | ||
| Q4 24 | $29.0M | $41.5M | ||
| Q3 24 | $60.0M | $53.5M | ||
| Q2 24 | $69.1M | $49.3M | ||
| Q1 24 | $55.3M | $51.2M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 3.92× | ||
| Q3 25 | 3.03× | 1.71× | ||
| Q2 25 | 1.15× | 2.47× | ||
| Q1 25 | 1.39× | 2.61× | ||
| Q4 24 | 0.76× | 1.81× | ||
| Q3 24 | 1.48× | 1.39× | ||
| Q2 24 | 1.82× | 2.38× | ||
| Q1 24 | 1.28× | 4.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
HTO
| Water Utility Services | $191.0M | 96% |
| Other | $8.4M | 4% |
